Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert

Assessment of cataract formation after intravitreal use of triamcinolone acetonid and triamcinolone/bevacizumab combination: 1 year results

Search Title by author or title

Session Details

Session Title: Presented Poster Session: IOL Opacification

Venue: Poster Village: Pod 1

First Author: : N.Palarie MOLDOVA

Co Author(s): :    T. Pasenco   L. Vudu                    

Abstract Details


The purpose of this randomized retrospective study is to assess cataract formation after intravitreal use of triamcinolon acetonid (IVTA) and triamcinolon/bevacizumab (IVTA/IVB) combination.


International Clinic, Orhei, Moldova State University of Medicine and Pharmacy "Nicolae Testemitanu", Chisinau, Moldova


There were 47 eyes of 35 patients with diabetic macular edema included in the study. Best corrected visual acuity was 0,3 ± 0,1 LogMAR. Patients were matched by age, gender and randomized into 2 groups: patients in the 1st group (n=23 eyes) received 3 monthly consecutive IVTA 2 mg injections, patients in the 2nd group received 3 monthly consecutive IVTA/IVB (2mg+1,25mg) injections.


The follow-up period varied from 12 months to 1,2 year. Patients were followed at week 2 after any injection, months 1, 3, 6 and 12 following last injection. Posterior subcapsular cataract formation was noticed in 7 eyes (30%) in the 1st group and in 2 eyes in the 2nd group (8%) at the end of the follow up period. Transient intraocular pressure (IOP) rise was observed in 4 eyes in the 1st group and in 3 eyes in the 2nd group. IOP came back to normal at the end of the follow up period.


IVTA/IVB (2mg+1,25mg) combined injections do not cause posterior subcapsular cataract formation as often as IVTA 2 mg alone in 1 year follow up period. Both types of injections do not cause permanent IOP rise in a long term follow up.

Financial Disclosure:


Back to previous